Bernhard Schmierer News Today

MBB core facilities and the SciLifeLab infrastructure contribute to the REMEDi4ALL project that kicks off with the ambition of establishing a European research and innovation eco-system facilitating fast and cost-effective patient-centric development and access to repurposed medicines.

(Mirror Daily, United States) – Two new studies have found that a groundbreaking DNA-editing technology called CRISPR-Cas9 could boost cancer risk in patients that use the tech to get rid of hereditary diseases. Researchers explained that the CRISPR tool can become cancer-causing when it is used to replace unhealthy genes with healthier ones. Two separate studies, one funded by Novartis and another one conducted by Sweden-based Karolinska Institutets, show that, during a CRISPR-Cas9 edit, the...